[PDF] Top 20 A New Era in the Management of the Hepatitis C

... In 2011, the American Association for the Study of Liver Diseases (AASLD) issued an updated version of its practice guidelines for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection [2]. ... See full document

... promising new DAAs in development that offer superior efficacy, improved toler- ability, and shorter duration of ...of hepatitis C treatment, are now within ...exciting new era of ... See full document

... Abstract: Hepatitis C virus (HCV) was identified for the first time more than 20 years ...the management of HCV-infected patients and will maintain its significance for new combination ... See full document

... The introduction of directly acting antiviral agents (DAAs) in the treatment of infections with hepatitis C virus (HCV) has revolutio- nised the fi eld. 1 Whereas even 5 years ago our clinics were full of ... See full document

... a new era in the management of chronic hepatitis ...the hepatitis C RNA-dependent RNA polymerase, is the backbone of chronic hepatitis C ...titis C ... See full document

... revolutionized hepatitis C treatment, they have also lead to new HCV RNA VL result ...the management of CHC patients in the past and how this is likely to change in the era of ... See full document

... HCV, hepatitis C virus; IFN, interferon; KHC, Kuwait Hepatology Club; LDV, ledipasvir; NS, nonstructural; CKD, chronic kidney disease; CTP, Child–Turcotte–Pugh; PEG, PEGylated; PIs, protease inhibitors; PR, ... See full document

... Patients are more likely to develop complications over a 5–10 year term (ie, liver fibrosis F3–F4) and will benefit most from the new triple therapies. Furthermore, patients with a good prognosis (ie, liver ... See full document

... Abstract: Eltrombopag is a 2nd generation thrombopoietin-receptor agonist. It binds with the thrombopoietin-receptors found on the surfaces of the megakaryocytes & increases platelet production. Many recent studies ... See full document

... To care for the increased number of individuals expected to be diagnosed with HCV, primary care providers will need to be able to provide initial management and, ultimately, treatment. Currently, many primary care ... See full document

... chronic hepatitis C, based on a bitherapy that combines peginterferon alpha-2a or -2b and ribavirin for all genotypes, and on a triple therapy with the addition of an antiprotease specifically for genotype ... See full document

... post-bevacizumab era will prove to be a challenging environment for the neuro-oncology com- munity in evaluating new salvage therapy, but one that for the first time may carry real ... See full document

... of hepatitis C virus (HCV), estimated to affect more than 150 million individuals globally, has proven a major health problem by causing liver cirrhosis and ... See full document

... and management of anemia with transfusions, erythropoiesis-stimulating agents (ESAs), androgens, and immunomodulatory ...signaling, new targeted JAK inhibitor therapies, such as ruxolitinib, are now ... See full document

... good resistance profi le as well. The rtA194T mutation in association with LAM-resistance may confer resistance to TDF, although both in vivo and in vitro studies regarding this mutation demonstrate confl icting results. ... See full document

... The recent increase in mental health problems probably reflects the fragmentation of social cohesion of modern society, with changes in family composition, work and living habits, peer communication and virtual-based ... See full document

... The recently approved interferon-free DAA (direct antiviral agents) regimens have shown not only to be effective in terms of sustained virological response (SVR) rates (> 90%) but also well tolerated in most ... See full document

... The management of constipation in the elderly is challenging both for patients and healthcare providers. Multiple reasons contribute to this phenomenon, such as the effects of aging on gut physiology, co-morbid ... See full document

... drug with meal: 205 to 1020 pg/mL (median: 390 pg/mL)]. In the 24 h-AUC values, a considerable interindividual variation was, again, observed [basal: range 150 to 1017 pg × h/mg (median 375 pg × h/mg); drug and fasting: ... See full document

... inhibitor of glycosphingolipid synthesis, has recently been authorized in the European Union, Brazil and South Korea for the treatment of progressive neurological symptoms in adult and pediatric patients, and represents ... See full document